Deutsche Bank AG Invests $26.77 Million in ANI Pharmaceuticals, Inc. $ANIP

Deutsche Bank AG acquired a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 323,443 shares of the specialty pharmaceutical company’s stock, valued at approximately $26,775,000.

Other institutional investors have also made changes to their positions in the company. KBC Group NV acquired a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at about $28,000. Advisors Asset Management Inc. bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth $28,000. Hantz Financial Services Inc. grew its stake in ANI Pharmaceuticals by 70.3% in the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after buying an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. bought a new position in ANI Pharmaceuticals in the 4th quarter worth $48,000. Finally, State of Wyoming acquired a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $50,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock opened at $75.35 on Friday. The stock has a 50-day simple moving average of $80.36 and a 200 day simple moving average of $78.88. The stock has a market capitalization of $1.73 billion, a price-to-earnings ratio of 16.24 and a beta of 0.44. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals, Inc. has a 12-month low of $70.15 and a 12-month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The company had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. During the same period in the previous year, the firm posted $1.80 earnings per share. The company’s revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Guggenheim dropped their price objective on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Canaccord Genuity Group reduced their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday, August 10th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Wall Street Zen lowered ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $105.83.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 3,162 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $77.00, for a total value of $243,474.00. Following the transaction, the senior vice president directly owned 75,534 shares of the company’s stock, valued at approximately $5,816,118. This trade represents a 4.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen P. Carey sold 2,850 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $81.36, for a total transaction of $231,876.00. Following the sale, the chief financial officer directly owned 174,693 shares of the company’s stock, valued at $14,213,022.48. This represents a 1.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 18,987 shares of company stock valued at $1,546,405 in the last three months. Company insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.